Type II Hypersensitivity-Antibody mediated cytotoxic Hypersensitivity

19,476 views 23 slides Jun 07, 2021
Slide 1
Slide 1 of 23
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23

About This Presentation

Type II Hypersensitivity is antibody-mediated immune reaction in which antibodies (IgG or IgM) are directed against cellular or extracellular matrix antigens with the resultant cellular destruction, functional loss, or damage to tissues.


Slide Content

Type II Hypersensitivity
AnupMuni Bajracharya

Type II Hypersensitivity
•refers to an antibody-mediated immune reaction.
•reactions involve IgGand IgMantibodies
•These antibodies are directed against cellular antigens, leading to cell
damage.
•So it involves antibody mediated destruction of cells. It is also known as
cytotoxic reaction.
•The killing of cell can occurs by one of the three mechanisms.
•Activatecomplement, resulting in an inflammatory response and lysisof
the targeted cells, (Complement mediated lysisof cell)
or
•they can be involved inantibody-dependent cell-mediated cytotoxicity
(ADCC)withcytotoxic T cells.
or
•Opsonisation
•The reaction time is minutes to hours and thus considered as immediate
hypersensitivity.

Opsonisation
ADCC
Complement mediated cell lysis
the modification of antigens
by opsonins(antibody) to
make them more accessible
to phagocytic cells

Type II Hypersensitivity
•In some cases, the antigen may be a self-antigen, in which case the
reaction would also be described as anautoimmune disease.
•In other cases, antibodies may bind to naturally occurring, but exogenous,
cell-surface molecules such as antigens associated with blood typing
found onred blood cells(RBCs).

Mechanism of Type II Hypersensitivity Reactions
•The reaction is completed in two phases –sensitization
phase and effector phase.
•A sensitization phaseleads to production of antibodies
that recognize substances or metabolites that accumulate
in cellular membrane structures.
•In the effector phase, target cells become coated with
antibodies which lead to cellular destruction.
•Antibody bound to a surface antigen can induce the death
of the antibody-bound cell by three distinct mechanisms –
•by activation of the complement system,
•cell destruction by antibody dependent cell mediated
cytotoxicity (ADCC) or
•by the process of opsonization.

Complement system is a system of
lytic enzyme which are usually
inactive in blood.
Enzymes of complement system are
activated by antigen-antibody
complex.
When antibody binds to antigen
(microorganism or RBC) they form
Ag-abcomplex.
Ag-abcomplex can activate
complement system by three
different mechanism-classical
pathway, alternate pathway and
lectinpathway.
Activated complement proceeds in
cascade mechanism.
When complement is activated on
the surface of cell (RBC) it causes
lysisof cell.
Complement mediated lysisof cell

➢Antibody binds with antigen by its Fab portion. However Fc region of antibody has
receptor on cytotoxic cells.
➢So, antibody cross link target cell (microorganism or RBC) with cytotoxic cells and
promote killing.
➢Most cytotoxic cells contain storage of hydrolytic and digestive enzymes. These
enzymes are released on the surface of target cell (MOs or RBC or target cell),
killing them.
➢Here antibody itself does not kill or destroy cell but rather mediate killing by
presenting antigen to cytotoxic cell.
➢Similarly cytotoxic cell depends upon antibody to bind antigen. So this mechanism
is known as Antibody dependent cell mediated cytotoxicity.
Antibody dependent cell mediated cytotoxicity (ADCC)

•When antigen enters into host body, antibodies are produced.
•Antibody binds to antigen through Fab region. Fc region of antibody
remains free.
•Phagocytic cells such as Neutrophils, macrophages and monocytes
have receptors that can bind to Fc region of antibody. The receptor is
known as FcR.
•In this case antibody molecule directly cross links antigen
(Microrganismor RBC or target cell) with phagocytic cells. This cross-
linkage activates phagocytic cells and increases the rate of
phagocytosis.
•This increased rate of phagocytosis by binding of antibody to antigen
is called Opsonization.
Opsonization

Some examples of Type II Hypersensitivity
•Transfusion reactions
•Hemolytic disease of the newborn
•Autoimmune hemolytic anemia,
agranulocytosis, and thrombocytopenia
•Specific drug reactions
•Glomerulonephritis
•Myasthenia gravis, Graves disease, and other
autoimmune disorders

•Common examples
•Hemolytic transfusion reaction (HTR)--
Transfusion reaction
•Hemolytic disease of the newborn (HDN)--
Rhesus incompatibility

ABO Blood Group Incompatibility
Therecognitionthatindividualshavedifferentbloodtypeswasfirstdescribed
byKarlLandsteiner(1868–1943)intheearly1900s,basedonhisobservation
thatserumfromonepersoncouldcauseaclumpingofRBCsfromanother.
ThesestudiesledLandsteinertotheidentificationoffourdistinctblood
types.

Transfusion reaction
•A patient may require ablood transfusionbecause they lack sufficient
RBCs (anemia).
•For instance, if a person with type B blood receives a transfusion of type A
blood, their anti-A antibodies will bind to andagglutinatethe transfused
RBCs.
•In addition, activation of theclassical complement cascadewill lead to a
strong inflammatory response, and the complementmembrane attack
complex (MAC)will mediate massivehemolysisof the transfused RBCs.
•The debris from damaged and destroyed RBCs can occlude blood vessels
in the alveoli of the lungs and the glomeruli of the kidneys.
•Within 1 to 24 hours of an incompatible transfusion, the patient
experiences fever, chills, pruritus (itching), urticaria(hives), dyspnea,
hemoglobinuria(hemoglobin in the urine), and hypotension (low blood
pressure).
•In the most serious reactions, dangerously low blood pressure can lead to
shock, multi-organ failure, and death of the patient.

Figure-A type II hypersensitivity hemolytic transfusion reaction (HTR) leading to hemolytic
anemia. Blood from a type A donor is administered to a patient with type B blood. The anti-A
isohemagglutininIgMantibodies in the recipient bind to and agglutinate the incoming donor
type A red blood cells. The bound anti-A antibodies activate the classical complement
cascade, resulting in destruction of the donor red blood cells.

Hemolytic disease of the newborn (HDN)
Rhesus incompatibility (Rh hemolytic disease)
•If an Rh− woman carries an Rh+ baby to term, the mother’s immune
system can be exposed toRh+ fetal red blood cells.
•This exposure will usually occur during the last trimester of pregnancy and
during the delivery process.
•If this exposure occurs, the Rh+ fetal RBCs will activate a primary adaptive
immune response in the mother, and anti-Rh factor IgGantibodies will be
produced.
•IgGantibodies are the only class of antibody that can cross the placenta
from mother to fetus; however, in most cases, the first Rh+ baby is
unaffected by these antibodies because the first exposure typically occurs
late enough in the pregnancy that the mother does not have time to
mount a sufficient primary antibody response before the baby is born.
•If a subsequentpregnancywith an Rh+ fetus occurs, however, the
mother’s second exposure to the Rh factor antigens causes a strong
secondary antibody response that produces larger quantities of anti-Rh
factor IgG. These antibodies can cross the placenta from mother to fetus
and cause HDN, a potentially lethal condition for the baby.

When an Rh− mother has an Rh+ fetus, fetal erythrocytes are introduced into the mother’s circulatory system before or
during birth, leading to production of anti-Rh IgGantibodies. These antibodies remain in the mother and, if she becomes
pregnant with a second Rh+ baby, they can cross the placenta and attach to fetal Rh+ erythrocytes. Complement-mediated
hemolysis of fetal erythrocytes results in a lack of sufficient cells for proper oxygenation of the fetus. (b) HDN can be
prevented by administering Rho(D) immune globulin during and after each pregnancy with an Rh+ fetus. The immune
globulin binds fetal Rh+ RBCs that gain access to the mother’s bloodstream, preventing activation of her primary immune
response.

Drug induced hemolytic anemia
This drug induced hemolytic
anemia is an example of Type II
hypersensitivity reaction.
Certain drugs such as penicillin,
cephalosporin and streptomycin
can absorb non-specifically to
protein on surface of RBC forming
complex similar to hepten-carrier
complex.
In some patients these complex
induce formation of antibodies,
which binds to drugs on RBC and
induce complement mediated
lysisof RBC and thus produce
progressive anemia

Cell Destruction due to Autoantigens
Antibodies to a variety of self antigens such as basement membranes of lung and
kidney (Goodpasture’sSyndrome), the acetylcholine receptor (Myasthenia Gravis)
and erythrocytes (Autoimmune Hemolytic Anemia) can result in tissue damaging
reactions.

Autoimmune Hemolytic Anemia

Myasthenia gravis

An example of a cytotoxic reaction isthrombocytopenia.
In this disease, antibody molecules are elicited by certain drug molecules. The
antibodies unite with antigens on the surface of thrombocytes (platelets), and with
complement activation, the thrombocytes are destroyed. The result is an impaired
blood-clotting mechanism.
Thrombocytopenia

Another example of the cytotoxic reaction isagranulocytosis.
In this immune disorder, antibodies unite with antigens on the surface of
neutrophils.
As these cells are destroyed with complement activation, the capacity for
phagocytosis is reduced.
Agranulocytosis